RT Conference Proceedings
T1 Durvalumab plus tremelimumab in patients with grade 3 neuroendocrine neoplasms of gastroenteropancreatic origin: Updated results from the multicenter phase II DUNE trial (GETNE 1601)
A1 Capdevila, J.
A1 Landolfi, S.
A1 Hernando, J.
A1 Teule, A.
A1 Garcia-Carbonero, R.
A1 Custodio, A.
A1 Cubillo, A.
A1 Alonso-Gordoa, T.
A1 Carmona-Bayonas, A.
A1 Crespo, G.
A1 Blanco, M.
A1 Viudez, A.
A1 La Casta, A.
A1 Sevilla, I.
A1 Segura, A.
A1 Lopez, C.
A1 Benavent Vinuales, M.
A1 Nuciforo, P.
A1 Manzano, J. L.
K1 Humans
K1 Neuroendocrine Tumors
K1 Survival Rate
K1 Carcinoid Tumor
K1 Gastrointestinal Neoplasms
K1 Treatment Outcome
K1 Lung
AB Background.Previously reported treatment efficacy with durvalumab (D) plus tremelimumab (T) showed limited activity in patients (pts) with well differentiated neuroendocrine tumors (NETs). However, primary endpoint was achieved in grade 3 (G3) neuroendocrine neoplasms (NENs) suggesting a promising overall survival rate in a pretreated population. Here we update the results of the G3 cohort with central pathological review.Methods.DUNE was a prospective open-label trial that recruited pts with advanced NENs after progression to standard therapies in four cohorts (C1-4): typical/atypical lung carcinoids (C1), G1/2 gastrointestinal (C2), G1/2 pancreatic (C3), and G3 NENs of gastroenteropancreatic origin after progression to first-line platinum-based chemotherapy (C4). Pts received 1500 mg durvalumab (D) (up to 13 cycles) plus 75 mg tremelimumab (T)(up to 4 cycles) once every 4 weeks. Primary objective for C4 was the 9 months (m) overall survival rate (OS) expected to be over 23%.
PB Elsevier
SN 0923-7534
YR 2021
FD 2021-09-21
LK https://hdl.handle.net/10668/27028
UL https://hdl.handle.net/10668/27028
LA en
NO J. Capdevila , S. Landolfi , J. Hernando , A. Teule , R. Garcia-Carbonero , A. Custodio, et al. Durvalumab plus tremelimumab in patients with grade 3 neuroendocrine neoplasms of gastroenteropancreatic origin: Updated results from the multicenter phase II DUNE trial (GETNE 1601). Annals of Oncology, 2021, (32), S914 - S915
DS RISalud
RD Apr 20, 2025